SEC Form 4 · accession 0001140361-19-004433
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward Wirth
Officer — Chief Medical Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 1, 2019 | A | 156,452 | $0.00 | A | 316,020 | D | |
| Common Stock | Mar 1, 2019 | F | 48,826 | $0.95 | D | 267,194 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF3 | $1.95 | holding | — | — | — | — | Mar 14, 2028 | Common Stock | 150,000 | 150,000 | D |
| Stock OptionsF4 | $2.34 | holding | — | — | — | — | Mar 9, 2020 | Common Stock | 192,500 | 192,500 | D |
| Stock OptionsF5 | $3.90 | holding | — | — | — | — | Feb 12, 2025 | Common Stock | 50,000 | 50,000 | D |
| Stock OptionsF6 | $3.64 | holding | — | — | — | — | Feb 25, 2026 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1The shares reported herein were awarded to the Reporting Person by the Issuer's Board of Directors upon recommendation by the Compensation Committee, in connection with the Company's 2018 bonus payment to the Reporting Person, in lieu of cash payment to the Reporting Person.
- F2Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the grant of shares reported herein.
- F3Subject to Mr. Wirth's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was March 14, 2018. The stock options are exercisable upon vesting.
- F4Subject to Mr. Wirth's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was March 10, 2013. The stock options are exercisable upon vesting.
- F5Subject to Mr. Wirth's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was February 26, 2015. The stock options are exercisable upon vesting.
- F6Subject to Mr. Wirth's continued employment with the Company, 25% of the granted stock options vest on the first anniversary of the grant date, and the remaining 75% of the stock options in equal monthly installments over 36 months commencing after the first anniversary of the grant date. The grant date of these options was February 26, 2016. The stock options are exercisable upon vesting.